Which statement best describes the risks of compounded or non-approved hormone therapy preparations?

Which statement best describes the risks of compounded or non-approved hormone therapy preparations?

• A. They are always safe and effective.
• B. They are approved and well-regulated.
• C. They carry risks of inconsistent dosing, lack of efficacy, and increased adverse effects.
• D. They have lower costs with no downsides.

Answer: (C)

The main idea is that compounded or non-approved hormone therapies carry safety and quality uncertainties because they aren’t evaluated as rigorously as FDA-approved medicines. Because these preparations are not subject to the same standardized testing and labeling, the amount of hormone in each batch can vary widely. That leads to inconsistent dosing, so symptom relief can be unpredictable and some patients may receive too little or too much hormone. Without solid clinical trial data backing their efficacy, there’s also a real possibility of lack of therapeutic benefit. In addition, the quality controls for compounding can be less stringent, increasing the risk of contamination, impurities, or incorrect ingredients, which can raise the incidence of adverse effects. In short, variable potency, uncertain effectiveness, and higher safety risks are the core reasons this option is the best description. The other statements falsely imply universal safety, strict regulation, or no downsides, which isn’t supported by how these products are overseen and studied.

The main idea is that compounded or non-approved hormone therapies carry safety and quality uncertainties because they aren’t evaluated as rigorously as FDA-approved medicines. Because these preparations are not subject to the same standardized testing and labeling, the amount of hormone in each batch can vary widely. That leads to inconsistent dosing, so symptom relief can be unpredictable and some patients may receive too little or too much hormone. Without solid clinical trial data backing their efficacy, there’s also a real possibility of lack of therapeutic benefit. In addition, the quality controls for compounding can be less stringent, increasing the risk of contamination, impurities, or incorrect ingredients, which can raise the incidence of adverse effects. In short, variable potency, uncertain effectiveness, and higher safety risks are the core reasons this option is the best description. The other statements falsely imply universal safety, strict regulation, or no downsides, which isn’t supported by how these products are overseen and studied.